Benzinga | Jan 24, 2022 04:28AM EST

SVB Leerink Maintains Outperform on Biogen, Lowers Price Target to $300

SVB Leerink analyst Marc Goodman maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $325 to $300.